Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROPECIA vs ADCIRCA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Finasteride is a competitive and specific inhibitor of type II 5α-reductase, an intracellular enzyme that converts testosterone to dihydrotestosterone (DHT). By inhibiting 5α-reductase, finasteride reduces serum and intraprostatic DHT levels, decreasing androgenic stimulation of the prostate. In hair follicles, reduction of DHT levels slows hair loss and promotes hair regrowth.
Phosphodiesterase-5 (PDE5) inhibitor; increases c GMP in pulmonary vascular smooth muscle, leading to vasodilation.
Treatment of male pattern hair loss (androgenetic alopecia) in men only,Treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate
Treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to improve exercise capacity and delay clinical worsening.,Off-label: Erectile dysfunction (not FDA-approved for this indication in the context of PAH).
1 mg orally once daily
10 mg orally three times daily.
Terminal elimination half-life is approximately 6-8 hours in young adults (range 4-12 hours), with clinical relevance for once-daily dosing; slightly prolonged in elderly (8-11 hours).
Terminal half-life: 10–15 hours in healthy adults; prolonged in hepatic impairment (Child-Pugh B/C: up to 30 hours); clinical context: supports twice-daily dosing
Finasteride is extensively metabolized in the liver, primarily via the cytochrome P450 3A4 enzyme system. Two major metabolites, t-butyl side chain hydroxylation and ω-hydroxylation, have been identified; these metabolites possess less than 20% of the 5α-reductase inhibitory activity of finasteride.
Primarily metabolized by CYP3A4 (major) and CYP2C9 (minor) hepatic enzymes.
Primarily hepatic metabolism; 57% excreted in feces (as metabolites), 39% in urine (as metabolites, <0.1% as unchanged finasteride).
Renal: ~70% (metabolites and unchanged drug), Fecal: ~20%, Biliary: minor
Approximately 93% bound to plasma proteins (mainly albumin).
96% bound to albumin and alpha-1-acid glycoprotein
Approximately 1.1 L/kg (range 0.9-1.3 L/kg), indicating extensive tissue distribution with penetration into seminal fluid and scalp tissue.
Vd: 0.4–0.7 L/kg; suggests distribution into total body water and moderate tissue binding
Oral bioavailability is approximately 65% (range 60-70%); not affected by food.
Oral: 80%; absolute bioavailability: 50% due to first-pass metabolism
No dose adjustment required for any degree of renal impairment
No dose adjustment required for mild to moderate renal impairment; avoid use in severe impairment (Cr Cl <30 m L/min) due to lack of data.
No dose adjustment recommended; no studies in hepatic impairment
Mild to moderate hepatic impairment (Child-Pugh A or B): 10 mg orally once daily; severe hepatic impairment (Child-Pugh C): contraindicated.
Not indicated in pediatric patients; safety and efficacy not established
Not established for patients <18 years.
No specific dose adjustment; limited data in elderly men with benign prostatic hyperplasia
No specific dose adjustment, but caution due to increased sensitivity; monitor renal function.
PROPECIA is not approved for use in women or children. Finasteride is contraindicated in women who are or may become pregnant due to risk of abnormalities of the external genitalia of a male fetus. Women should not handle crushed or broken tablets when pregnant or may be pregnant.
Do not use in patients taking nitrates (regularly or intermittently) due to risk of severe hypotension.
Risk of prostate cancer: Finasteride may increase the risk of high-grade prostate cancer; digital rectal exam and PSA screening recommended before and during therapy.,Sexual dysfunction: Decreased libido, erectile dysfunction, ejaculation disorders, and decreased ejaculate volume have been reported; may persist after discontinuation.,Depression and suicidal ideation: Monitor for mood changes.,Breast cancer: Reported in men; evaluate any breast changes promptly.,Elevated PSA levels: Use caution interpreting PSA values in men on finasteride; adjust PSA levels by approximately 50% for clinical interpretation.,Hepatic impairment: Use with caution in patients with liver function abnormalities.,Pediatric use: Not indicated for use in children.
Risk of hypotension, especially with nitrates or alpha-blockers.,Hematologic effects: increased risk of bleeding due to antiplatelet activity; caution with bleeding disorders or anticoagulants.,Vision loss: non-arteritic anterior ischemic optic neuropathy (NAION) has been reported; discontinue if sudden vision loss occurs.,Hearing loss: sudden decrease or loss of hearing; may be accompanied by tinnitus or dizziness.,Use caution in patients with left ventricular outflow obstruction (e.g., aortic stenosis) or severely impaired autonomic control of blood pressure.,Dose adjustment required with strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir).
Hypersensitivity to finasteride or any component of the formulation,Women who are or may become pregnant (due to risk of hypospadias in male fetuses),Children (not indicated for use in pediatric patients)
Concomitant use of nitrates (any form) or nitric oxide donors.,Concomitant use with riociguat or other guanylate cyclase stimulators.,Known hypersensitivity to tadalafil or any component of the product.,Severe hepatic impairment (Child-Pugh class C).
No clinically significant food interactions. May be taken with or without food. However, avoid excessive alcohol intake as it may exacerbate certain side effects (e.g., dizziness).
Avoid grapefruit and grapefruit juice as they may increase tadalafil levels and risk of side effects. No other significant food interactions. High-fat meals may delay absorption but do not require dose adjustment.
Contraindicated in females of childbearing potential. Finasteride inhibits conversion of testosterone to DHT, and risk of hypospadias in male fetuses if exposure occurs during gestation. No adequate studies in pregnant women; animal studies show abnormal external genitalia in male offspring at doses 1-100 times human exposure.
Pregnancy Category B. Animal studies have not demonstrated fetal risk, but there are no adequate and well-controlled studies in pregnant women. First trimester: risk cannot be ruled out; use only if clearly needed. Second and third trimesters: no known fetal risks, but caution advised due to maternal hypotension risk.
Not recommended. M/P ratio unknown. Finasteride is excreted in rat milk; no human data.
Not recommended. Excretion in human milk unknown. M/P ratio not established. Risk of hypotension in neonate. Alternative feeding method advised during therapy and for 48 hours after last dose.
No dose adjustments applicable as drug is contraindicated in pregnancy.
No specific pharmacokinetic data in pregnancy. Standard dose (40 mg orally once daily) recommended. Monitor for hypotension; dose adjustment not routinely required unless maternal hypotension develops.
Monitor patients for sexual dysfunction (e.g., decreased libido, erectile dysfunction) which may persist after discontinuation. Finasteride lowers serum PSA by approximately 50%; when interpreting PSA values in men taking Propecia, double the measured value for prostate cancer screening. Use with caution in patients with liver impairment; hepatic metabolism is primary clearance route. Avoid handling crushed or broken tablets in women who are or may become pregnant due to risk of teratogenicity (fetal genital abnormalities). Onset of hair regrowth typically takes 3-6 months; continue use for at least 12 months before assessing efficacy.
Adcirca (tadalafil) is a PDE5 inhibitor indicated for pulmonary arterial hypertension (PAH) to improve exercise ability. It is dosed at 40 mg once daily, not as needed. Avoid use with nitrates due to risk of severe hypotension. Monitor for vision loss (non-arteritic anterior ischemic optic neuropathy) and hearing loss. Use caution in patients with hepatic impairment (Child-Pugh class B: reduce dose; class C: contraindicated). Dose adjustment required with potent CYP3A4 inhibitors (e.g., ketoconazole: reduce to 20 mg). Not recommended for severe renal impairment (Cr Cl <30 m L/min) or on hemodialysis.
Take exactly as prescribed, usually one tablet (1 mg) daily with or without food.,Do not stop or skip doses without consulting your doctor; continuous use is needed to maintain benefit.,It may take 3-6 months to see hair regrowth and up to 12 months for full effect.,Report any new or worsening sexual side effects (e.g., decreased libido, erectile dysfunction, ejaculation disorders) promptly.,Finasteride may increase the risk of high-grade prostate cancer; discuss screening risks with your doctor.,Do not donate blood while taking Propecia and for at least 1 month after stopping to prevent exposure to pregnant women.,Women who are pregnant or may become pregnant should not handle crushed or broken tablets due to risk of birth defects.,If a dose is missed, skip it and take the next dose at the usual time; do not double up.
Take Adcirca exactly as prescribed, 40 mg once daily, at the same time each day. Do not take it as needed for erectile dysfunction.,Do not take Adcirca if you are taking any form of nitrate medication (e.g., nitroglycerin) or recreational drugs called 'poppers' (amyl nitrate) as this can cause a sudden dangerous drop in blood pressure.,Seek immediate medical attention if you experience sudden vision loss or decrease in hearing, as these may be signs of a serious side effect.,Avoid drinking large amounts of alcohol (e.g., 3 or more drinks) within a short time while taking Adcirca, as it may increase the risk of dizziness, lightheadedness, and fainting.,Inform your healthcare provider about all medications you take, including prescription, over-the-counter, and herbal products, especially alpha-blockers, erythromycin, or ritonavir.,Adcirca may cause dizziness. Do not drive or operate machinery until you know how the medicine affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROPECIA vs ADCIRCA, answered by our medical review team.
PROPECIA is a 5-alpha reductase inhibitor that works by Finasteride is a competitive and specific inhibitor of type II 5α-reductase, an intracellular enzyme that converts testosterone to dihydrotestosterone (DHT). By inhibiting 5α-reductase, finasteride reduces serum and intraprostatic DHT levels, decreasing androgenic stimulation of the prostate. In hair follicles, reduction of DHT levels slows hair loss and promotes hair regrowth.. ADCIRCA is a PDE5 Inhibitor that works by Phosphodiesterase-5 (PDE5) inhibitor; increases c GMP in pulmonary vascular smooth muscle, leading to vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROPECIA and ADCIRCA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROPECIA is: 1 mg orally once daily. The standard adult dose of ADCIRCA is: 10 mg orally three times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROPECIA and ADCIRCA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROPECIA is classified as Category C. Contraindicated in females of childbearing potential. Finasteride inhibits conversion of testosterone to DHT, and risk of hypospadias in male fetuses if exposure occurs during gest. ADCIRCA is classified as Category C. Pregnancy Category B. Animal studies have not demonstrated fetal risk, but there are no adequate and well-controlled studies in pregnant women. First trimester: risk cannot be rule. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.